215 related articles for article (PubMed ID: 27183528)
1. Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection.
Deidda M; Madonna R; Mango R; Pagliaro P; Bassareo PP; Cugusi L; Romano S; Penco M; Romeo F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S76-83. PubMed ID: 27183528
[TBL] [Abstract][Full Text] [Related]
2. Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection.
Deidda M; Madonna R; Mango R; Pagliaro P; Bassareo PP; Cugusi L; Romano S; Penco M; Romeo F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e76-e83. PubMed ID: 27755245
[TBL] [Abstract][Full Text] [Related]
3. Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection.
Deidda M; Mercurio V; Cuomo A; Noto A; Mercuro G; Cadeddu Dessalvi C
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590338
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of anthracycline cardiotoxicity.
Mele D; Tocchetti CG; Pagliaro P; Madonna R; Novo G; Pepe A; Zito C; Maurea N; Spallarossa P
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S3-S11. PubMed ID: 27183523
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
Bassareo PP; Monte I; Romano C; Deidda M; Piras A; Cugusi L; Coppola C; Galletta F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S55-63. PubMed ID: 27183526
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.
Jain D; Russell RR; Schwartz RG; Panjrath GS; Aronow W
Curr Cardiol Rep; 2017 May; 19(5):36. PubMed ID: 28374177
[TBL] [Abstract][Full Text] [Related]
7. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection.
Madonna R; Cadeddu C; Deidda M; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Spallarossa P; Tocchetti CG; Zito C; Mercuro G
Heart Fail Rev; 2015 Sep; 20(5):621-31. PubMed ID: 26168714
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of cancer chemotherapy in clinical practice.
Jain D; Aronow W
Hosp Pract (1995); 2019 Feb; 47(1):6-15. PubMed ID: 30270693
[TBL] [Abstract][Full Text] [Related]
10. Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs.
Mercurio V; Pirozzi F; Lazzarini E; Marone G; Rizzo P; Agnetti G; Tocchetti CG; Ghigo A; Ameri P
J Card Fail; 2016 Jun; 22(6):449-58. PubMed ID: 27103426
[TBL] [Abstract][Full Text] [Related]
11. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.
Cadeddu C; Mercurio V; Spallarossa P; Nodari S; Triggiani M; Monte I; Piras R; Madonna R; Pagliaro P; Tocchetti CG; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S64-75. PubMed ID: 27183527
[TBL] [Abstract][Full Text] [Related]
12. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
13. Current views on anthracycline cardiotoxicity.
Mele D; Nardozza M; Spallarossa P; Frassoldati A; Tocchetti CG; Cadeddu C; Madonna R; Malagù M; Ferrari R; Mercuro G
Heart Fail Rev; 2016 Sep; 21(5):621-34. PubMed ID: 27230651
[TBL] [Abstract][Full Text] [Related]
14. Heart failure and chemotherapeutic agents.
Piper S; McDonagh T
Future Cardiol; 2015 Jul; 11(4):453-70. PubMed ID: 26234158
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology of anthracycline cardiotoxicity.
Mele D; Tocchetti CG; Pagliaro P; Madonna R; Novo G; Pepe A; Zito C; Maurea N; Spallarossa P
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e3-e11. PubMed ID: 27755237
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
Nelson-Veniard M; Thambo JB
Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer.
Mihalcea DJ; Florescu M; Vinereanu D
Am J Ther; 2017; 24(1):e3-e11. PubMed ID: 27145188
[TBL] [Abstract][Full Text] [Related]
18. Acute and Chronic Effects of Cancer Drugs on the Cardiovascular System.
Moriyama S; Fukata M; Kusaba H; Maruyama T; Akashi K
Heart Fail Clin; 2020 Apr; 16(2):231-241. PubMed ID: 32143767
[TBL] [Abstract][Full Text] [Related]
19. Antiblastic drug-induced cardiotoxicity and cardioprotection: a compendium.
Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e1-e2. PubMed ID: 27755236
[No Abstract] [Full Text] [Related]
20. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]